Related Experiment Video
Updated: Jan 21, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy
Jian-Feng Zheng1, Shaozhong He2, Zongyue Zeng3
1Department of Laboratory Medicine, Baoan Central Hospital of Shenzhen, The Fifth Affiliated Hospital of Shenzhen University, Shenzhen 518102, Guangdong, P.R. China.
Abstract:
Hepatocellular carcinoma (HCC) tumors invariably develop resistance to cytotoxic and targeted agents, resulting in failed treatment and tumor recurrence. Previous in vivo short hairpin RNA (shRNA) screening evidence revealed mitochondrial-processing peptidase (PMPC) as a leading gene contributing to tumor cell resistance against sorafenib, a multikinase inhibitor used to treat advanced HCC. Here, we investigated the contributory role of the β subunit of PMPC (PMPCB) in sorafenib resistance. Silencing PMPCB increased HCC tumor cell susceptibility to sorafenib therapy, decreased liver tumor burden, and improved survival of tumor-bearing mice receiving sorafenib. Moreover, sorafenib + PMPCB shRNA combination therapy led to attenuated liver tumor burden and improved survival outcome for tumor-bearing mice, and it reduced colony formation in murine and human HCC cell lines in vitro. Additionally, PMPCB silencing enhanced PINK1-Parkin signaling and downregulated the anti-apoptotic protein MCL-1 in sorafenib-treated HCC cells, which is indicative of a healthier pro-apoptotic phenotype. Higher pre-treatment MCL-1 expression was associated with inferior survival outcomes in sorafenib-treated HCC patients. Elevated MCL-1 expression was present in sorafenib-resistant murine HCC cells, while MCL-1 knockdown sensitized these cells to sorafenib. In conclusion, our findings advocate combination regimens employing sorafenib with PMPCB knockdown or MCL-1 knockdown to circumvent sorafenib resistance in HCC patients.
Insights
Targeting mitochondrial-processing peptidase beta subunit (PMPCB) can overcome sorafenib resistance in hepatocellular carcinoma (HCC). Silencing PMPCB or MCL-1 enhances sorafenib efficacy, improving survival outcomes for HCC patients.
Area of Science:
- Hepatocellular carcinoma (HCC) research
- Cancer therapy resistance mechanisms
- Molecular oncology
Background:
- Hepatocellular carcinoma (HCC) frequently develops resistance to targeted therapies like sorafenib, leading to treatment failure.
- Mitochondrial-processing peptidase (PMPC) has been identified as a key contributor to sorafenib resistance in HCC.
- The specific role of the PMPC beta subunit (PMPCB) in this resistance mechanism requires further investigation.
Purpose of the Study:
- To investigate the role of PMPCB in sorafenib resistance in hepatocellular carcinoma (HCC).
- To evaluate the therapeutic potential of targeting PMPCB in combination with sorafenib for HCC treatment.
- To elucidate the molecular mechanisms underlying PMPCB-mediated sorafenib resistance.
Main Methods:
- Utilized short hairpin RNA (shRNA) to silence PMPCB in HCC cell lines and tumor-bearing mice.
- Assessed tumor cell susceptibility to sorafenib, liver tumor burden, and animal survival.
- Investigated the impact of PMPCB silencing on PINK1-Parkin signaling and MCL-1 expression.
- Correlated pre-treatment MCL-1 expression with survival outcomes in HCC patients.
Main Results:
- Silencing PMPCB significantly increased HCC cell sensitivity to sorafenib, reduced tumor burden, and improved survival in mice.
- Combination therapy with sorafenib and PMPCB shRNA attenuated tumor growth and enhanced survival.
- PMPCB knockdown promoted apoptosis by activating PINK1-Parkin signaling and downregulating MCL-1.
- Higher pre-treatment MCL-1 levels correlated with poorer survival in sorafenib-treated HCC patients.
Conclusions:
- PMPCB plays a crucial role in mediating sorafenib resistance in hepatocellular carcinoma.
- Targeting PMPCB, potentially through knockdown strategies, offers a promising approach to overcome sorafenib resistance.
- Combination therapy involving sorafenib with PMPCB or MCL-1 knockdown presents a viable strategy to improve treatment outcomes for advanced HCC patients.
More Related Videos
08:00The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Gene Therapy
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Group Therapy
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Psychodynamic Therapy
Humanistic Therapy